At PILL.AR, we have developed and patented MESO-PP®, a revolutionary additive manufacturing method that enables the automated production of personalized medications with pharmaceutical precision and quality, directly at the patient’s point of care. Our innovative “smart factory” technology decentralizes medication production, allowing pharmacies to create individualized solutions that combine nutraceuticals and medications in the exact doses each person needs.
Through our platform, we connect patients with healthcare professionals and centers that develop, design, and prescribe comprehensive, hyper-personalized treatments that are medically validated.
With PILL.AR, the future of personalized medicine is accessible to everyone.
Because patients are adapting to the industry, rather than the industry adapting to patients.
More than 40% of older adults take more than five medications a day.
Polypharmacy is the main cause of treatment abandonment.
Preventive treatments require dose adjustments and combinations that are not available on the market.
Over-the-counter products often contain standardized, suboptimal doses.
We aim to become the first global health platform, fully verticalized and deep tech-driven, built on advanced science and materials technology, to address multiple health conditions. Our goal is to put the patient at the center, providing integrated, personalized, high-quality care from start to finish, enabling an integral health and wellness experience that meets each person’s unique needs and expectations.
PILL.AR is a disruptive startup founded in July 2023 by a team combining science, business, and innovation. With over 20 years of experience in research, materials science, pharmaceutical technology, and production transformation, our founders bring a track record of excellence and commitment to the industry, spanning more than two generations of pharmacists.
PILL.AR is based in the UNC Business Incubator, powering a technology developed by the National University of Córdoba and CONICET. In 2023, we received investment from SF500, a company builder aiming to generate over 500 startups in the next 10 years.
